Literature DB >> 8752808

Digoxin reduces cardiac sympathetic activity in severe congestive heart failure.

G E Newton1, J H Tong, A M Schofield, A D Baines, J S Floras, J D Parker.   

Abstract

OBJECTIVES: This study evaluated the effect of digoxin on cardiac sympathetic activity in patients with congestive heart failure.
BACKGROUND: Digoxin favorably alters autonomic tone in heart failure. Whether it reduces cardiac sympathetic drive in the setting of heart failure is unknown.
METHODS: Digoxin (0.25 mg intravenously) was administered to 12 patients with severe heart failure and elevated left ventricular end-diastolic pressure (> 14 mm Hg, Group A), 5 patients with less severe heart failure who had normal left ventricular end-diastolic pressure (> 14 mm Hg, Group B) and 6 patients with normal ventricular function. Seven additional patients with heart failure were studied as a time control group. Cardiac and total body norepinephrine spillover, systemic arterial pressure, left ventricular filling pressure and peak positive first derivative of left ventricular pressure were all assessed before and 30 min after administration of digoxin.
RESULTS: In Group A there were no changes in hemodynamic variables or total body norepinephrine spillover after digoxin administration; however, there was a significant reduction in cardiac norepinephrine spillover (263 +/- 70 to 218 +/- 62 pmol/min, mean +/- SEM, p < 0.001). In contrast, in Group B, digoxin caused a significant increase in cardiac norepinephrine spillover that was not associated with any hemodynamic changes or a change in total body spillover. There were no hemodynamic changes or a change in total body spillover. There were no hemodynamic or spillover changes in the time control or normal ventricular function group.
CONCLUSIONS: Digoxin, in the absence of detectable inotropic or hemodynamic effects, caused a reduction in cardiac norepinephrine spillover in patients with heart failure who had elevated filling pressures. This finding suggests a potentially beneficial primary autonomic action of digoxin in patients with severe heart failure.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8752808     DOI: 10.1016/0735-1097(96)00120-9

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  11 in total

1.  To add amiodarone or not: that is the question.

Authors:  Matthew Jason Zimmerman; Myron C Gerson
Journal:  J Nucl Cardiol       Date:  2008 Jan-Feb       Impact factor: 5.952

2.  Angiotensin AT1 receptor blockade abolishes the reflex sympatho-excitatory response to adenosine.

Authors:  G A Rongen; S C Brooks; S i Ando; B L Abramson; J S Floras
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

Review 3.  Is Heart Rate a Norepiphenomenon in Heart Failure?

Authors:  Mark Hensey; James O'Neill
Journal:  Curr Cardiol Rep       Date:  2016-09       Impact factor: 2.931

Review 4.  Should beta-blockers be used for the treatment of pediatric patients with chronic heart failure?

Authors:  Luke A Bruns; Charles E Canter
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

5.  Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure.

Authors:  Ali Ahmed; Robert C Bourge; Gregg C Fonarow; Kanan Patel; Charity J Morgan; Jerome L Fleg; Inmaculada B Aban; Thomas E Love; Clyde W Yancy; Prakash Deedwania; Dirk J van Veldhuisen; Gerasimos S Filippatos; Stefan D Anker; Richard M Allman
Journal:  Am J Med       Date:  2013-11-18       Impact factor: 4.965

6.  Digoxin use and lower risk of 30-day all-cause readmission in older patients with heart failure and reduced ejection fraction receiving β-blockers.

Authors:  Phillip H Lam; Poonam Bhyan; Cherinne Arundel; Daniel J Dooley; Helen M Sheriff; Selma F Mohammed; Gregg C Fonarow; Charity J Morgan; Wilbert S Aronow; Richard M Allman; Finn Waagstein; Ali Ahmed
Journal:  Clin Cardiol       Date:  2018-03-22       Impact factor: 2.882

7.  Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial.

Authors:  Mihai Gheorghiade; Kanan Patel; Gerasimos Filippatos; Stefan D Anker; Dirk J van Veldhuisen; John G F Cleland; Marco Metra; Inmaculada B Aban; Stephen J Greene; Kirkwood F Adams; John J V McMurray; Ali Ahmed
Journal:  Eur J Heart Fail       Date:  2013-01-25       Impact factor: 15.534

8.  Potential effects of digoxin on long-term renal and clinical outcomes in chronic heart failure.

Authors:  Jeffrey M Testani; Meredith A Brisco; W H Wilson Tang; Stephen E Kimmel; Anjali Tiku-Owens; Paul R Forfia; Steven G Coca
Journal:  J Card Fail       Date:  2013-05       Impact factor: 5.712

Review 9.  Prevention of and medical therapy for atrial arrhythmias in heart failure.

Authors:  A U Khand; J G F Cleland; P C Deedwania
Journal:  Heart Fail Rev       Date:  2002-07       Impact factor: 4.214

10.  Restoration of normal sympathetic neural function in heart failure following baroreflex activation therapy: final 43-month study report.

Authors:  Raffaella Dell'Oro; Edoardo Gronda; Gino Seravalle; Giuseppe Costantino; Luca Alberti; Barbara Baronio; Tiziana Staine; Emilio Vanoli; Giuseppe Mancia; Guido Grassi
Journal:  J Hypertens       Date:  2017-12       Impact factor: 4.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.